medigraphic.com
Colegio de Medicina Interna de México.

2024, Number 10

<< Back Next >>

Med Int Mex 2024; 40 (10)

Personalized medicine

Cerón LS, Martínez SLM, Senior BPA

Language: Spanish
References: 40
Page: 657-663
PDF size: 322.33 Kb.


ABSTRACT

Precision medicine is a term that has become very popular in recent times, which explains that each individual has different characteristics at molecular, physiological, epigenetic and behavioral level. Therefore, every patient should receive interventions that are adaptable to either one. DNA contains genes that are part of the genetic code, which oversees synthesizing protein. To study this process, five sciences were created: proteomics, transcriptomic, epigenomic, metabolomic and pharmacogenomics. Through these techniques, modern medicine is evolving, trying to pursue adjusted therapies, less exposure to ineffective or toxic medication, greater adherence to the treatment and increased patient participation in their recovery process. Some illnesses that could be treated by precision medicine are neoplastic processes, autoimmune and cardiovascular diseases. However, to accomplish these precise treatments it is required infrastructure, trained professional team, economic resources in healthcare and other considerations that could obstruct the applicability of this new medical practice.


REFERENCES

  1. Hurtado C. Medicina de precisión: conceptos, aplicacionesy proyecciones. Rev Med Clin Condes 2022; 33 (1): 7-16.doi 10.1016/j.rmclc.2022.01.002

  2. Goetz LH, Schork NJ. Personalized medicine: motivation,challenges, and progress. Fertil Steril 2018; 109 (6): 952-63.doi: 10.1016/j.fertnstert.2018.05.006

  3. Hassan M, Awan FM, Naz A, deAndrés-Galiana EJ, et al.Innovations in genomics and big data analytics for personalizedmedicine and health care: A review. Int J Mol Sci 2022;23 (9): 4645. doi: 10.3390/ijms23094645

  4. Ginsburg GS, Willard HF. Genomic and personalized medicine:foundations and applications. Transl Res 2009; 154(6): 277-87. doi: 10.1016/j.trsl.2009.09.005

  5. Cirillo D, Valencia A. Big data analytics for personalizedmedicine. Curr Opin Biotechnol 2019; 58: 161-7. doi:10.1016/j.copbio.2019.03.004

  6. Chan IS, Ginsburg GS. Personalized medicine: progress andpromise. Annu Rev Genomics Hum Genet 2011; 12: 217-44.doi: 10.1146/annurev-genom-082410-101446

  7. Hernández J, Serrano O. La medicina personalizada, larevolución genómica y el Sistema Nacional de Salud. RevCubana de Salud Pública 2014; 40 (4): 379-91.

  8. Hurtado C. Medicina de precisión: conceptos, aplicacionesy proyecciones. Rev Med Clin Condes 2022; 33 (1): 7-16.doi 10.1016/j.rmclc.2022.01.002

  9. National Institutes of Health (US); Biological SciencesCurriculum Study. NIH Curriculum Supplement Series [Internet].Bethesda (MD): National Institutes of Health (US);2007. Understanding Human Genetic Variation. Availablefrom: https://www.ncbi.nlm.nih.gov/books/NBK20363/

  10. Ho D, Quake SR, McCabe ERB, Chng WJ, et al. EnablingTechnologies for Personalized and Precision Medicine.Trends Biotechnol 2020; 38 (5): 497-518. doi: 10.1016/j.tibtech.2019.12.021

  11. Ashley EA. Towards precision medicine. Nat Rev Genet2016; 17 (9): 507-22. doi: 10.1038/nrg.2016.86

  12. Hamburg MA, Collins FS. The path to personalized medicine.N Engl J Med 2010; 363 (4): 301-4. doi: 10.1056/NEJMp1006304

  13. Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C,Borowski C, et al. Toward understanding and exploitingtumor heterogeneity. Nat Med 2015; 21 (8): 846-53. doi:10.1038/nm.3915

  14. Duffy DJ. Problems, challenges and promises: perspectiveson precision medicine. Brief Bioinform 2016; 17 (3): 494-504. doi: 10.1093/bib/bbv060

  15. Liang K-H. Chapter 3: Transcriptomics. In: Woodhead PublishingSeries in Biomedicine, Bioinformatics for BiomedicalScience and Clinical Applications. Woodhead Publishing2013: 49-82.

  16. Aslam B, Basit M, Nisar MA, Khurshid M, Rasool MH.Proteomics: Technologies and their applications. J ChromatogrSci 2017; 55 (2): 182-96. doi: 10.1093/chromsci/bmw167

  17. Clish CB. Metabolomics: an emerging but powerful tool forprecision medicine. Cold Spring Harb Mol Case Stud 2015;1 (1): a000588. doi: 10.1101/mcs.a000588

  18. Moreno M, Wielandt AM, Encina G, Ortiz L. Farmacogenéticaen psiquiatría: estudio de variantes alélicas delcyp450 en pacientes chilenos con patología psiquiátrica.Rev Med Clin Condes 2021; 33 (1): 58-67. 10.1016/j.rmclc.2021.12.004

  19. Rivas S, Armisén R. El cáncer de pulmón de células nopequeñas en la era de la medicina de precisión. Rev MedClin Condes 2022; 33 (1): 25-35. https://doi.org/10.1016/j.rmclc.2022.01.001

  20. Raez LE, Cardona AF, Santos ES, Catoe H, et al. The burdenof lung cancer in Latin-America and challenges in the accessto genomic profiling, immunotherapy and targetedtreatments. Lung Cancer 2018; 119: 7-13. doi: 10.1016/j.lungcan.2018.02.014

  21. Raby BA, D M, PH M. Personalized medicine. Uptodate2021.

  22. Hampel H, Gao P, Cummings J, Toschi N, et al. The foundationand architecture of precision medicine in neurologyand psychiatry. Trends Neurosci 2023; 46 (3): 176-198. doi:10.1016/j.tins.2022.12.004

  23. Rodríguez WFL, Ramírez AJL. Medicina personalizada,individualizada, de precisión y centrada en el paciente; diferenciaso sinónimos. Su importancia. Acta Med GA 2022; 20(1): 111-112. https://dx.doi.org/10.35366/103572

  24. Quiroz T., Las Heras F. Medicina de precisión: rol de laanatomía patológica en diagnóstico y tratamiento personalizado.Rev Med Clin Condes 2022; 33 (1): 36-43.doi:10.1016/j.rmclc.2022.01.003

  25. Acevedo F, Sánchez C, Walbaum B. Terapia personalizadaen cáncer de mama precoz. Implicancias prácticas. RevMed Clin Condes 2022; 33 (1): 17-24. doi:/10.1016/j.rmclc.2021.12.002

  26. Fornacon-Wood I, Faivre-Finn C, O’Connor JPB, Price GJ.Radiomics as a personalized medicine tool in lung cancer:Separating the hope from the hype. Lung Cancer 2020; 146:197-208. doi: 10.1016/j.lungcan.2020.05.028

  27. Bieber K, Kridin K, Emtenani S, Boch K, Schmidt E, LudwigRJ. Milestones in Personalized Medicine in Pemphigusand Pemphigoid. Front Immunol 2021; 11: 591971. doi:10.3389/fimmu.2020.591971.

  28. Giusti D, Le Jan S, Gatouillat G, Bernard P, Pham BN,Antonicelli F. Biomarkes related to bullous pemphigoidactivity and outcome. Exp Dermatol 2017; 26: 1240-7. doi:10.1111/exd.13459

  29. Giusti D, Gatouillat G, Le Jan S, Plée J, et al. Eosinophilcationic protein (ECP), a predictive marker of bullous pemphigoidseverity. Sci Rep 2017; 7 (1): 4833. doi: 10.1038/s41598-017-04687-5

  30. Riani M, Le Jan S, Plé EJ, Durlach A, et al. Bullous pemphigoidoutcome is associated with CXCL10-induced matrixmetalloproteinase 9 secretion from monocytes and neutrophilsbut not lymphocytes. J Allergy Clin Immunol 2016;139 (3): 863-72. doi: 10.1016/ j.jaci.2016.08.012

  31. Giusti D, Gatouillat G, Le Jan S, Plée J, et al. Anti-type VIIcollagen antibodies are identified in a subpopulation ofbullous pemphigoid patients with relapse. Front Immunol2018; 9: 570. doi: 10.3389/fimmu.2018.00570

  32. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, et al. Heartdisease and stroke statistics-2013 update: a report fromthe American Heart Association. Circulation 2013; 127: e6.https://doi.org/10.1161/CIR.0b013e31828124ad

  33. Gómez E. Capítulo 2. Introducción, epidemiología de lafalla cardiaca e historia de las clínicas de falla cardiaca enColombia. Rev Colomb Cardiol 2016; 23: 6-12.

  34. Currie G, Delles C. Precision medicine and personalizedmedicine in cardiovascular disease. Adv Exp Med Biol2018; 1065: 589-605. doi: 10.1007/978-3-319-77932-4_36

  35. Bannister AJ, Kouzarides T. Regulation of chromatin by histonemodifications. Cell Res 2011; 21 (3): 381-95. https://doi. org/10.1038/cr.2011.22.

  36. Gillette TG, Hill JA. Readers, writers and erasers: chromatinas the whiteboard of heart disease. Circ Res 2015; 116(7): 1245-53. https://doi.org/10.1161/CIRCRESAHA.116.303630

  37. Anaya JM, Duarte-Rey C, Sarmiento-Monroy JC, BardeyD, et al. Personalized medicine. Closing the gap betweenknowledge and clinical practice. Autoimmun Rev 2016; 15(8): 833-42. doi: 10.1016/j.autrev.2016.06.005

  38. Gaviria GLM. medicina personalizada: ¿un conceptoexclusivo de los países desarrollados? Universidae de losAndes, Colombia 2018.

  39. Pritchard DE, Moeckel F, Villa MS, Housman LT, et al. Strategiesfor integrating personalized medicine into healthcarepractice. Per Med 2017; 14 (2): 141-152. doi: 10.2217/pme-2016-0064

  40. Mitropoulos K, Cooper DN, Mitropoulou C, Agathos S, etal. Genomic medicine without borders: Which strategiesshould developing countries employ to invest in precisionmedicine? A new “fast-second winner” strategy. OMICS2017; 21 (11): 647-657. doi: 10.1089/omi.2017.0141




2020     |     www.medigraphic.com